Related by context. All words. (Click for frequent words.) 80 mCRC 79 advanced NSCLC 78 NSCLC 76 metastatic breast cancer 76 hormone refractory prostate cancer 74 metastatic renal cell carcinoma 73 mRCC 72 HRPC 72 metastatic melanoma 71 renal cell carcinoma 70 HER2 positive metastatic breast 70 Vectibix 70 cetuximab 69 mCRC patients 69 docetaxel 69 chronic lymphocytic leukemia CLL 69 cell lung cancer 68 chemotherapy regimens 68 HER2 positive 68 axitinib 67 HER2 positive breast cancer 67 sorafenib 67 erlotinib 67 gemcitabine 67 sunitinib 66 B CLL 66 hepatocellular cancer 66 metastatic CRC 66 lymphoma CTCL 66 SCCHN 66 indolent NHL 65 FOLFIRI 65 castration resistant prostate cancer 65 vandetanib 65 soft tissue sarcoma 65 Amrubicin 65 assessing T DM1 65 FOLOTYN 65 metastatic pancreatic cancer 65 bevacizumab 65 HER2 + 65 KRAS wild 65 brain metastases 65 non squamous NSCLC 65 temozolomide 65 refractory multiple myeloma 65 temsirolimus 65 capecitabine 65 gastrointestinal stromal tumor GIST 64 malignant pleural mesothelioma 64 solid tumors 64 gemcitabine chemotherapy 64 Torisel 64 irinotecan 64 gastrointestinal stromal tumors 64 follicular lymphoma 64 multiple myeloma 64 carboplatin paclitaxel 64 pemetrexed 64 dasatinib 64 recurrent NSCLC 64 metastatic colon cancer 64 platinum refractory 64 unresectable 64 metastatic carcinoma 64 glufosfamide 64 resistant ovarian cancer 64 Taxotere ® 64 chronic myeloid leukemia CML 64 adjuvant therapy 64 docetaxel chemotherapy 64 leukemia CLL 64 carboplatin 63 bendamustine 63 IMGN# 63 acute myeloid leukemia AML 63 metastatic 63 CLL 63 panitumumab 63 metastatic renal cell 63 gefitinib 63 trastuzumab 63 superficial bladder cancer 63 gastric cancer 63 Metastatic Colorectal Cancer 63 TORISEL 63 Fludara 63 rituximab 63 tyrosine kinase inhibitors 63 metastatic colorectal 63 colorectal cancer 63 phase IIb clinical 63 relapsed ovarian cancer 63 biologic therapy 63 perifosine 63 bevacizumab Avastin 63 relapsed refractory multiple myeloma 63 hepatocellular carcinoma HCC 63 KRAS status 63 prostate cancer CRPC 63 recurrent ovarian cancer 63 cutaneous T cell 62 T DM1 62 sorafenib Nexavar 62 vinorelbine 62 refractory metastatic colorectal cancer 62 dacarbazine 62 pazopanib 62 metastatic RCC 62 OncoVEX GM CSF 62 GIST 62 monotherapy 62 IRESSA 62 Taxotere R 62 pancreatic adenocarcinoma 62 heavily pretreated 62 Irinotecan 62 taxane 62 hematologic malignancies 62 bevacizumab Avastin ® 62 medullary thyroid cancer 62 EGFR expressing mCRC 62 chemotherapy regimen 62 HER2 negative 62 multiple myeloma MM 62 non squamous 62 cetuximab Erbitux 62 fludarabine 61 oxaliplatin 61 FOLFOX 61 metastatic prostate cancer 61 metastatic disease 61 prostate cancer HRPC 61 adecatumumab 61 pancreatic NET 61 oral ridaforolimus 61 metastatic hormone refractory 61 glioblastoma multiforme GBM 61 trabectedin 61 gastrointestinal stromal tumors GIST 61 evaluating T DM1 61 chemoradiotherapy 61 unresectable locally advanced 61 malignancies 61 T#I mutation 61 aflibercept 61 cetuximab Erbitux ® 61 chlorambucil 61 EGFR expressing 61 pegylated liposomal doxorubicin 61 Halaven 61 glioblastoma 61 registrational trial 61 recurrent GBM 61 Nexavar sorafenib 61 relapsed refractory 61 Sutent 61 Ceflatonin 61 diagnosed multiple myeloma 61 ipilimumab 61 pertuzumab 61 cancer mCRC 61 standard chemotherapy regimens 61 nilotinib 61 hematological cancers 61 factor receptor EGFR 61 dasatinib Sprycel ® 61 enzastaurin 60 randomized Phase III 60 YONDELIS 60 Nexavar 60 paclitaxel carboplatin 60 bortezomib 60 IV melanoma 60 TEMODAL 60 metastatic GIST 60 Avastin 60 sunitinib malate 60 Erbitux 60 metastatic castration resistant 60 nab paclitaxel 60 HGS ETR1 60 fluoropyrimidine 60 cisplatin 60 Targretin 60 carcinoma 60 IV metastatic melanoma 60 5 fluorouracil 60 advanced unresectable 60 metastatic NSCLC 60 TREANDA 60 SUTENT 60 cell lymphoma CTCL 60 EGFR mutation 60 Avastin bevacizumab 60 sorafenib Nexavar ® 60 chemoradiation 60 imatinib resistant 60 elacytarabine 60 refractory CTCL 60 recurrent glioblastoma multiforme 60 ERBITUX 60 OPAXIO 60 refractory Hodgkin lymphoma 60 Velcade bortezomib 60 liver metastases 60 metastatic castrate resistant 60 hepatocellular carcinoma 60 Afinitor 60 stage IIIB 60 mapatumumab 60 pomalidomide 60 cediranib 60 Acute Myeloid Leukemia AML 60 amrubicin 60 refractory NSCLC 60 ® cetuximab 60 metastatic CRPC 60 castrate resistant prostate cancer 60 free survival PFS 60 carfilzomib 60 tamibarotene 60 VELCADE 60 lapatinib 60 ZEVALIN 60 Tarceva 59 relapsed multiple myeloma 59 EFAPROXYN 59 docetaxel Taxotere ® 59 Tykerb 59 refractory AML 59 AVASTIN 59 refractory PTCL 59 Folotyn 59 erlotinib Tarceva ® 59 Herceptin trastuzumab 59 zalutumumab 59 5 FU 59 IV NSCLC 59 neoadjuvant chemotherapy 59 paclitaxel 59 obatoclax 59 neuroendocrine tumors 59 CoFactor 59 lupus nephritis 59 Pemetrexed 59 imatinib 59 hormone receptor positive 59 picoplatin 59 Erbitux cetuximab 59 decitabine 59 metastatic cancer 59 Genasense 59 myelodysplastic syndromes MDS 59 clofarabine 59 EGFR mutations 59 Satraplatin 59 standard chemotherapy regimen 59 Fludara ® 59 mycophenolate mofetil 59 Hepatocellular Carcinoma HCC 59 Xeloda 59 metastatic colorectal carcinoma 59 plus gemcitabine 59 topotecan 59 Hycamtin 59 recurrent glioblastoma 59 leukemia AML 59 chemotherapeutic agent 59 nonsmall cell lung cancer 59 pralatrexate 59 follicular NHL 59 Tarceva erlotinib 59 taxane therapy 59 ADVEXIN 59 relapsing MS 59 FOLFOX4 59 infusional 5-FU/LV 59 idiopathic pulmonary fibrosis IPF 59 Genasense ® 59 ofatumumab 59 metastatic HRPC 59 relapsed SCLC 59 ixabepilone 58 AP# [003] 58 acute myelogenous leukemia AML 58 TTF Therapy 58 ELOXATIN 58 ASA# 58 lintuzumab 58 Cloretazine 58 histone deacetylase HDAC inhibitor 58 trastuzumab Herceptin ® 58 alkylating agent 58 Doxil ® 58 iniparib 58 azacitidine 58 5-FU/LV 58 palifosfamide 58 plus dexamethasone 58 pegylated interferon alpha 58 non metastatic osteosarcoma 58 FOLFIRI alone 58 docetaxel Taxotere R 58 afatinib 58 gemcitabine carboplatin 58 VIDAZA 58 Clolar 58 hematological malignancies 58 Nexavar ® 58 relapsed GBM 58 relapsed CLL 58 ganetespib 58 gefitinib Iressa 58 MabCampath 58 dasatinib Sprycel 58 metastatic malignant melanoma 58 REVLIMID 58 unresectable stage 58 mTOR inhibitor 58 colorectal cancer CRC 58 Proxinium TM 58 imatinib Gleevec 58 sapacitabine 58 imatinib Gleevec ® 58 metastatic gastric 58 follicular lymphoma FL 58 Sorafenib 58 metastatic SCCHN 58 IMA# 58 cetuximab Erbitux R 58 HCV SPRINT 58 advanced hepatocellular carcinoma 58 Erlotinib 58 imatinib therapy 58 LUX Lung 58 CHOP chemotherapy 58 Rituxan rituximab 58 fallopian tube carcinoma 58 anthracyclines 58 TYKERB 58 tyrosine kinase inhibitor 58 bone metastasis 58 Cloretazine ® 58 sarcoma 58 liposomal doxorubicin 58 Jevtana 58 chemotherapeutic regimen 58 tocilizumab 58 relapsing remitting multiple sclerosis 58 panitumumab Vectibix 58 figitumumab 58 Aplidin 58 EGFR TKI 58 soft tissue sarcomas 58 TACE 58 XELOX 58 dirucotide 58 Taxotere 58 heavily pretreated patients 58 vemurafenib 58 Aflibercept 58 sipuleucel T 58 tesmilifene 58 irinotecan chemotherapy 58 luteinizing hormone releasing 58 pancreatic neuroendocrine tumors 58 tumors GIST 58 BRIM3 58 bone metastases 58 alvespimycin 58 olaparib 58 ELACYT 58 Cell Lung Cancer 58 docetaxel Taxotere 58 paclitaxel Taxol 58 receptor tyrosine kinase inhibitor 58 carcinoid tumors 57 registrational 57 Revlimid lenalidomide 57 Gleevec resistant 57 recurrent colorectal cancer 57 adjuvant chemotherapy 57 pegylated interferon 57 Rituxan 57 IgG1 monoclonal antibody 57 Xcytrin 57 tesetaxel 57 IRX 2 57 myelofibrosis 57 relapsing multiple sclerosis 57 basal cell carcinoma BCC 57 neoadjuvant treatment 57 Hodgkin lymphoma HL 57 Perifosine 57 cytarabine 57 regorafenib 57 Revlimid 57 Reolysin 57 RG# [001] 57 Brentuximab Vedotin SGN 57 capecitabine Xeloda R 57 sorafenib tablets 57 Bevacizumab 57 randomized Phase 57 refractory chronic lymphocytic 57 FOLFOX6 57 myeloma 57 lymphomas 57 radiation sensitizer 57 BCIRG 57 metastatic squamous cell carcinoma 57 refractory APL 57 Tamibarotene 57 MyVax R 57 acute promyelocytic leukemia APL 57 antitumor activity 57 FOLFOX regimen 57 malignant melanoma 57 anti TNF 57 DLBCL 57 Pixantrone 57 Trastuzumab 57 neoadjuvant therapy 57 Alemtuzumab 57 Advexin 57 Amigal 57 leukemia ALL 57 systemic lupus erythematosus 57 plus prednisone 57 lumiliximab 57 pain palliation 57 depsipeptide 57 melanoma 57 investigational compound 57 BRAF inhibitor 57 recurrent malignant glioma 57 systemic ALCL 57 refractory acute myeloid 57 Xeloda capecitabine 57 Xelox 57 Evoltra TM 57 custirsen 57 lapatinib Tykerb 57 HGS# 57 DMARD 57 immunotherapeutic agent 57 GW# [003] 57 FTY# 57 Acute Myelogenous Leukemia AML 57 XGEVA 57 Nexavar tablets 57 5FU 57 Allovectin 7 57 Treanda 57 seliciclib 57 Ixempra 57 refractory ovarian cancer 57 opioid induced constipation OIC 57 Imprime PGG 57 colorectal liver metastases 57 FOLFIRI chemotherapy 57 voreloxin 57 myelodysplastic syndrome MDS 57 ZACTIMA 57 CYT# potent vascular disrupting 57 stage IIIB IV 57 Gemzar ® 57 evaluating Xcytrin 57 taxane chemotherapy 56 CTCL 56 HuMax CD4 56 androgen independent 56 refractory CLL 56 remission induction 56 adjuvant radiation 56 belinostat 56 operable breast cancer 56 Gleevec imatinib 56 prostate cancer mCRPC 56 chronic myelogenous leukemia CML 56 PROVENGE ® 56 Pirfenidone 56 cytotoxic chemotherapy 56 OMAPRO 56 trastuzumab Herceptin R 56 anti EGFR antibody 56 invasive candidiasis 56 Troxatyl 56 Vectibix panitumumab 56 RoACTEMRA 56 stage IIIb 56 TRISENOX 56 L MTP PE 56 trastuzumab Herceptin 56 Dacogen injection 56 Kit CD# positive 56 gastrointestinal stromal tumor 56 gemcitabine Gemzar 56 cabazitaxel 56 antibody MAb 56 cilengitide 56 Oncophage 56 metastatic kidney 56 Hodgkin lymphoma NHL 56 5 fluorouracil leucovorin 56 metastatic pancreatic 56 Velcade 56 Gefitinib 56 Phase 2b clinical 56 Fludarabine 56 nucleoside analogue 56 BCG refractory 56 CANCIDAS 56 bosutinib 56 satraplatin 56 thalidomide Thalomid 56 irinotecan containing 56 stage IIIb IV 56 T#I [002] 56 cancers 56 abiraterone acetate 56 Tavocept 56 relapsing remitting MS 56 tanespimycin 56 abiraterone 56 chronic ITP patients 56 Azixa 56 ZYBRESTAT 56 Everolimus 56 Chronic Lymphocytic Leukemia 56 R sorafenib tablets 56 chemotherapeutic agents 56 PXD# 56 maraviroc 56 Dasatinib 56 advanced metastatic renal 56 differentiated thyroid 56 Campath alemtuzumab 56 Phase Ib study 56 Clolar ® 56 adalimumab 56 NOXAFIL 56 Ozarelix 56 KRAS mutations occur 56 Provenge 56 HCV RESPOND 2 56 Bezielle 56 pegylated interferon alfa 2a 56 mutated KRAS gene 56 leucovorin 56 epithelial ovarian cancer 56 epithelial tumors 56 EGFR mutation positive 56 Actemra 56 eculizumab 56 metastatic lung cancer 56 vismodegib 56 MabThera 56 surrogate endpoint 56 taxanes 56 romiplostim 56 locoregional 56 Folfox 56 resectable 56 Phase 2b trial 56 posaconazole 56 entinostat 56 K ras 56 CR# vcMMAE 56 neoplasia 56 eltrombopag 56 Vidaza 56 MOZOBIL 56 aflibercept VEGF Trap 56 Cetuximab 56 AEG# 56 Zolinza 56 colorectal cancer liver metastases 56 follicular non 56 APPRAISE 56 evaluating ispinesib 56 TELCYTA 56 Campath 56 BR.# 56 myelodysplastic syndromes 56 Annamycin 56 Lapatinib 56 neratinib 56 metastatic cancers 56 HNSCC 56 Yervoy 56 forodesine 56 CLARITY study 56 localized prostate cancer 56 chronic lymphocytic leukemia 56 histologies 56 hepatitis C HCV 56 achieve sustained virologic 56 prostate cancer AIPC 56 SUCCEED trial 55 SCH # 55 PEGINTRON 55 anti angiogenic therapy 55 XL# [003] 55 CVP chemotherapy 55 eribulin mesylate 55 vascular disrupting agent 55 tyrosine kinase inhibitor TKI 55 eribulin 55 low dose cytarabine 55 ponatinib 55 cisplatin chemotherapy 55 GvHD 55 BAY #-# 55 EGFR inhibitors 55 multi kinase inhibitor 55 Voreloxin 55 KRAS mutant tumors 55 Non Hodgkin Lymphoma 55 evaluating tivozanib 55 nilotinib Tasigna ® 55 resminostat 55 EGFR tyrosine kinase inhibitors 55 phase IIa clinical 55 pixantrone 55 interferon alfa 55 trastuzumab DM1 T DM1 55 valopicitabine 55 Votrient 55 bortezomib Velcade 55 cladribine 55 recurrent metastatic 55 dose escalation clinical 55 HGS ETR2 55 EGFR 55 Omnitarg 55 imatinib mesylate Gleevec 55 CMV disease 55 zoledronic acid 55 invasive aspergillosis 55 Phenoptin 55 predictive biomarker 55 refractory cutaneous T 55 melphalan prednisone 55 Vicinium TM 55 tofacitinib 55 Dacogen 55 goserelin 55 pegfilgrastim 55 CRPC 55 Pralatrexate 55 metastatic breast 55 Degarelix 55 DMARDs 55 unresectable liver cancer 55 Carboplatin 55 adenocarcinoma 55 Allovectin 7 ® 55 ABRAXANE 55 KRAS mutation 55 HCV infection 55 MabThera Rituxan 55 pancreatic carcinoma 55 acute leukemias 55 DCVax R Brain 55 RSR# 55 Metastatic 55 trastuzumab DM1 55 squamous cell carcinoma 55 Mylotarg 55 prostate cancers 55 symptomatic BPH 55 L BLP# 55 Sutent sunitinib 55 letrozole 55 seminoma 55 doxorubicin HCl liposome injection 55 Platinol 55 lymphoid malignancies 55 CALGB # [001] 55 liver cancer 55 Junovan 55 idarubicin 55 KRAS 55 nonmetastatic 55 VFEND 55 Surgical resection 55 INCB# [001] 55 Marqibo 55 randomized controlled Phase 55 Chronic Lymphocytic Leukemia CLL 55 Multiple Myeloma 55 cutaneous T 55 endocrine therapy 55 pulmonary arterial hypertension PAH 55 Sprycel 55 metastatic malignant 55 PROVENGE 55 CellCept 55 relapsing remitting MS RRMS 55 EOquin 55 hormonal therapy 55 gastrointestinal cancers 55 ovarian cancer 55 diabetic nephropathy 55 radioimmunotherapy 55 anti leukemic 55 HCV infected 55 refractory colorectal cancer 55 Phase Ib 55 interferon alfa 2a 55 Triapine 55 Taxotere chemotherapy 55 cangrelor 55 BEXXAR 55 Carfilzomib 55 MGd 55 Bortezomib 55 sarcomas 55 alkylating agents 55 CBLC# 55 Actimmune ® 55 pivotal Phase III 55 ToGA 55 Certican 55 Vandetanib 55 refractory chronic myeloid 55 blinatumomab 55 cell malignancies 55 Multiple Myeloma MM 55 Noxafil 55 TheraSphere 55 pivotal Phase 55 Rituximab 55 evaluating picoplatin 55 BRIM2 55 Cytoxan 55 EGFR expressing metastatic colorectal 55 Onco TCS 55 PROSTVAC ® 55 Vidaza R 55 galiximab 55 COU AA 55 Tarceva TM 55 capecitabine Xeloda 55 brentuximab vedotin 55 Azedra 55 Alimta 55 peginterferon 54 EGFr 54 recurrent prostate cancer 54 Gleevec imatinib mesylate 54 Clofarabine 54 anastrozole 54 daunorubicin 54 previously untreated follicular 54 acute ischemic stroke 54 systemic lupus erythematosus SLE 54 situ CIS 54 UPLYSO 54 metastatic androgen independent 54 lenalidomide Revlimid R 54 Glioblastoma Multiforme 54 AA amyloidosis 54 cytotoxic therapy 54 MAGE A3 ASCI 54 IL# PE#QQR 54 Ph + ALL 54 INCB# [002] 54 recurrent glioma 54 FOLFOX chemotherapy 54 Zevalin 54 sunitinib Sutent 54 AVADO 54 cholangiocarcinoma 54 Glufosfamide 54 Ceplene/IL-2 54 phase IIb trial 54 anticancer therapy 54 tyrosine kinase inhibitors TKIs 54 chemotherapy cisplatin 54 ADXS# 54 fallopian tube cancers 54 ribavirin RBV 54 fidaxomicin 54 Gemcitabine 54 CA4P 54 carcinomas 54 imetelstat 54 Taxotere docetaxel 54 Myelofibrosis 54 distant metastasis 54 Cloretazine R 54 ustekinumab 54 Adjuvant chemotherapy 54 TKIs 54 BRAF mutation 54 colorectal 54 tivozanib 54 relapsed MM 54 OvaRex ® MAb 54 lorvotuzumab mertansine 54 pulmonary arterial hypertension 54 Yondelis 54 Hycamtin ® 54 K RAS 54 bladder cancers 54 Arranon 54 ISEL 54 MDV# 54 Romiplostim 54 phenoxodiol 54 romidepsin 54 VELCADE melphalan 54 Phase 2b study 54 dacarbazine chemotherapy 54 Onrigin 54 pan HDAC inhibitor 54 KRAS mutant 54 trabedersen 54 chronic angina 54 refractory gout 54 CLL SLL 54 urothelial bladder cancer 54 bucindolol 54 invasive bladder 54 oral deforolimus 54 thromboembolic events 54 Metastatic breast cancer 54 Tasigna nilotinib 54 Golimumab 54 vorinostat 54 Bendamustine 54 cell lymphomas 54 TNFerade 54 anthracycline 54 NSABP 54 TroVax 54 EOquin TM 54 interferon gamma 1b 54 Advanced Renal Cell 54 investigational therapies 54 Phase 2a trial 54 Phase Ib II 54 Acute Myeloid Leukemia 54 Xyotax 54 Prostate AdenoCarcinoma Treatment 54 personalized immunotherapy 54 TKI therapy 54 non Hodgkin lymphoma 54 entecavir 54 chemotherapy 54 Insegia 54 Abraxane 54 xenograft models 54 biliary tract cancer 54 GVAX 54 thymalfasin 54 chronic hepatitis C. 54 Navelbine ® 54 CAELYX 54 PROSTVAC TM 54 Pegasys ® 54 colorectal cancers 54 IMC A# 54 PegIntron 54 anthracycline taxane 54 aHUS 54 PDX pralatrexate 54 Ceplene 54 Non Hodgkin lymphoma 54 untreated multiple myeloma 54 refractory metastatic 54 visilizumab 54 Panzem R NCD 54 tumor shrinkage 54 Myelodysplastic Syndrome MDS 54 IMPACT IMmunotherapy 54 ozarelix 54 relapsed 54 anthracycline containing 54 Gleevec Glivec 54 oblimersen 54 Temsirolimus 54 albinterferon alfa 2b 54 gastric cancers 54 PROVENGE sipuleucel T 54 Doxil 54 Epratuzumab 54 elagolix 54 Follicular Lymphoma 54 GnRH agonists 54 anthracyclines taxanes 54 Targretin capsules 54 squamous cell cancer 54 Quinamed 54 metaglidasen 54 myeloproliferative disorders 54 XL# SAR# 54 doublet chemotherapy 54 mitoxantrone 54 DCVax ® Brain 54 INC# 54 PREZISTA r 54 Gleevec 54 proteasome inhibitor 54 nilotinib Tasigna 54 HER2 54 acute myeloid leukemia 54 Mantle Cell Lymphoma 54 REOLYSIN ® 54 HCV genotype 54 Ocrelizumab 54 dose escalation trial 54 celgosivir 54 abatacept 54 REVLIMID ® 54 palliative radiotherapy 54 randomized Phase IIb 54 HuMax EGFr 54 Pertuzumab 54 PEGINTRON TM 54 HER2 positive cancers 54 Raptiva ® 54 advanced nonsquamous NSCLC 54 adriamycin 54 deforolimus 54 Omacetaxine 54 Navelbine 54 Xanafide 54 sustained virologic response 54 ofatumumab HuMax CD# 54 raltegravir 54 peginterferon alfa 2a 54 phase Ib 54 neoadjuvant 54 MYDICAR ® 54 PROLARIS 54 glatiramer acetate 54 Peginterferon alfa 2b 54 PKC# 54 complete remissions 54 Evoltra 54 biliary cancer 54 ACTEMRA TM 54 evaluating REVLIMID 53 ribavirin therapy 53 Her2 53 Phase #/#a trial 53 lamivudine 53 squamous cell 53 pediatric acute lymphoblastic 53 Lenalidomide 53 trastuzumab emtansine T DM1 53 bazedoxifene 53 VICTRELIS 53 cell chronic lymphocytic 53 talactoferrin 53 randomized multicenter Phase III 53 KRAS mutations 53 teriflunomide 53 XYOTAX 53 boosted protease inhibitor 53 Phase IIIb clinical 53 chemotherapies 53 fluorouracil 53 HBeAg positive patients 53 nimotuzumab 53 gemcitabine Gemzar ® 53 cell lymphoma 53 ovarian carcinoma 53 leukemia APL 53 autologous cellular immunotherapy 53 PEGylated interferon beta 1a 53 anti TNF alpha 53 sustained virological response 53 mitomycin 53 doxorubicin 53 NovoTTF 53 Cloretazine R VNP#M 53 Diabetic Macular Edema 53 medically inoperable 53 severe sepsis 53 SJIA 53 PLX# 53 iclaprim 53 viral kinetic 53 etoposide 53 GISTs 53 talabostat 53 Neulasta ® 53 noninferiority 53 Neoadjuvant 53 micafungin 53 disease progression 53 Imatinib 53 boceprevir 53 evaluable patients